Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4794 - Prognostic factors for overall survival of patients with advanced renal cell carcinoma – data from the German prospective RCC-Registry


10 Sep 2017


Poster display session


Renal Cell Cancer


Peter Goebell


Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371


P.J. Goebell1, L. Müller2, M. Staehler3, M. Müller4, M. Frank5, L. Kruggel6, M. Jänicke6, N. Marschner7

Author affiliations

  • 1 Department Of Urology, University Erlangen, 91054 - Erlangen/DE
  • 2 Medical Oncology, Onkologie Leer–Emden–Papenburg, 26789 - Leer/DE
  • 3 Dept Of Urology, University of Munich, Munich/DE
  • 4 Centre For Haematology And Oncology Offenburg, Centre for Haematology and Oncology Offenburg, Offenburg/DE
  • 5 Statistics, iOMEDICO AG, 79108 - Freiburg/DE
  • 6 Clinical Epidemiology And Health Economics, iOMEDICO AG, 79108 - Freiburg/DE
  • 7 Praxis Für Interdisziplinäre Onkologie & Hämatologie, Praxis für interdisziplinäre Onkologie & Hämatologie, 79110 - Freiburg/DE


Abstract 4794


The identification of prognostic factors is a central question in oncology. They help to predict the course of disease and ideally support the oncologist in treatment decision making in clinical practice. We analysed prognostic factors identified by MSKCC and additional factors for the overall survival (OS) of patients (pts) treated with currently approved agents.


The prospective German renal cell carcinoma (RCC) Registry includes pts with advanced or metastatic renal cell carcinoma at start of systemic first-line therapy. > 300 oncologists are recruiting pts since 2007. Pts and tumour characteristics, data on all systemic therapies and outcome are collected. The prognostic factors for OS were assessed using a multivariate cox regression model.


Median OS of the 1039 pts (median age 70 years) was 18.6 months (95% CI 16.0 - 20.5 months, 55% events). Median OS in months for low, intermediate and high risk pts according to MSKCC 1999 was 27.3 (23.7-33.8, 48% events), 16.0 (12.7-18.8, 58% events) and 5.3 (3.7-7.2, 74% events). The following factors were significantly associated with shorter OS (p 


3 out of 5 MSKCC factors were significantly associated with OS in our cohort. Still, a clear separation of OS between pts with low, intermediate and high risk according to MSKCC could be confirmed. In addition, we identified novel factors also associated with OS.

Clinical trial identification

ClinicalTrial.gov registry: study number: NCT00610012

Legal entity responsible for the study



Bayer Vital GmbH, GlaxoSmithKline GmbH & Co. KG, Novatis Pharma GmbH, Pfizer Pharma GmbH, Roche Pharma AG


P.J. Goebell: Received honoraria for paticipation in expert rounds and honoraria/support as a speaker from Astellas, AstraZeneca, Bayer, Bristol-Myers Squib, Eisai, Ipsen, Janssen, Novartis, Pfizer, Sanofi. M. Staehler: Consultant, Honoria and Research Funding: Pfizer, GlaxoSmithKline, Novartis, Bayer, AVEO, Ipsen, Exelixis, EISAI Consultant and Honoria: EUSAPharm, Astellas, Pelloton Consultant and Research funding: Roche Research funding: Immatics, Wilex. N. Marschner: Employed by iOMEDICO which performs the tumorregistry RCC as an CRO Member of advisory boards regarding RCC treatment and Travel grants: Roche, Novartis, Pfizer, Bayer, GSK Corporate sponsored research: Novartis, Pfizer Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.